Statement of Prospects

We are encouraged with our Group performance in this first half and remain confident in our ability to deliver strong year end results. In the second half of the year we expect to see continued strong profit growth from our Rapid Detection division which will balance the consolidation of our Analytical Services division, with our In Vitro Technologies division continuing to perform to expectations.

Our strategies to offer leading edge technologies and laboratory services that help our customers save both time and money from pre-clinical drug development through product manufacture to final supply chain management are well received by our pharmaceutical and consumer product customers. We remain confident that we have assembled a combined business offering which will deliver a strong year end performance and are enthusiastic about the Company’s long term prospects.

31 October 2007